Hologic, Inc. (HOLX) Stock

About Hologic, Inc.

Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.

Hologic, Inc. is headquartered in US.

Hologic, Inc. (HOLX) stock trades at $76.01 with a market capitalization of $16.97B. The stock is valued at a price-to-earnings (P/E) ratio of 31.28, price-to-book of 3.25, price-to-sales of 4.11. Over the past 52 weeks the stock has ranged between $51.90 and $76.07, and currently trades at its 52-week high.

On profitability, Hologic, Inc. generates a return on equity (ROE) of 11.01%, return on capital employed of 8.77%, an operating margin of 17.49%, a net profit margin of 13.18%.

In its most recent fiscal year, Hologic, Inc. reported annual revenue of $4.1B, net profit of $566.0M, revenue has compounded at 1.7% a year over the last five years, profit at -12.7% a year.

The balance sheet shows a debt-to-equity ratio of 0.48 — a conservative balance sheet with little leverage risk, a current ratio of 4.04, total assets of $9.0B, $2.0B in cash and equivalents.

HOLX has an average daily trading volume of 4,486,440 shares, a beta of 0.70 (less volatile than the overall market).

Official website: www.hologic.com